Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Hepatitis 1Hematologic Neoplasms 1Colitis, Ulcerative 1Colitis 1

Interventions

Nivolumab 21pembrolizumab 19Ipilimumab 14Specimen Handling 12Magnetic Resonance Spectroscopy 7Opdualag 6CTLA-4 Antigen 6relatlimab 5binimetinib 5trametinib 4Paclitaxel 4dabrafenib 3Taxes 3Standard of Care 3Pemetrexed 3Introns 3Interferon alpha-2 3Gemcitabine 3Carboplatin 3Blood Specimen Collection 3ulixertinib 2sargramostim 2lifileucel 2lenvatinib 2fludarabine phosphate 2fludarabine 2encorafenib 2capivasertib 2cabozantinib 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Infliximab × 30 days × Clear all
NCT07619898 2026-06-02

PHOENIX-ECP

Therakos LLC

Phase 2 Not yet recruiting
112 enrolled
Dermatologic

Colitis, Hepatitis, Melanoma

NCT05034536 2026-05-18

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

Massachusetts General Hospital

Phase 2 Active not recruiting
36 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡